Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TMEM123

Gene summary for TMEM123

Gene summary.

Gene information	Species	Human
	Gene symbol	TMEM123
	Gene ID	114908
	Gene name	transmembrane protein 123
	Gene Alias	KCT3
	Cytomap	11q22.2
	Gene Type	protein-coding
	GO ID	GO:0008150
	UniProtAcc	Q8N131

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
114908	TMEM123	GSM4909282	Human	Breast	IDC	4.05e-09	3.91e-01	-0.0288
114908	TMEM123	GSM4909285	Human	Breast	IDC	1.41e-50	7.72e-01	0.21
114908	TMEM123	GSM4909286	Human	Breast	IDC	3.98e-04	8.31e-02	0.1081
114908	TMEM123	GSM4909287	Human	Breast	IDC	1.03e-04	3.04e-01	0.2057
114908	TMEM123	GSM4909290	Human	Breast	IDC	3.69e-16	5.84e-01	0.2096
114908	TMEM123	GSM4909291	Human	Breast	IDC	1.09e-14	-5.58e-01	0.1753
114908	TMEM123	GSM4909293	Human	Breast	IDC	1.98e-02	-1.73e-01	0.1581
114908	TMEM123	GSM4909294	Human	Breast	IDC	1.96e-02	-2.05e-01	0.2022
114908	TMEM123	GSM4909296	Human	Breast	IDC	2.59e-10	-2.78e-01	0.1524
114908	TMEM123	GSM4909297	Human	Breast	IDC	3.57e-24	-4.98e-01	0.1517
114908	TMEM123	GSM4909298	Human	Breast	IDC	2.82e-02	-1.51e-02	0.1551
114908	TMEM123	GSM4909301	Human	Breast	IDC	4.85e-07	-4.00e-01	0.1577
114908	TMEM123	GSM4909302	Human	Breast	IDC	2.54e-04	-2.66e-01	0.1545
114908	TMEM123	GSM4909306	Human	Breast	IDC	5.38e-07	-3.92e-01	0.1564
114908	TMEM123	GSM4909308	Human	Breast	IDC	2.64e-02	-2.38e-01	0.158
114908	TMEM123	GSM4909309	Human	Breast	IDC	8.09e-05	-2.15e-01	0.0483
114908	TMEM123	GSM4909311	Human	Breast	IDC	8.51e-31	-5.65e-01	0.1534
114908	TMEM123	GSM4909312	Human	Breast	IDC	4.99e-11	-3.55e-01	0.1552
114908	TMEM123	GSM4909313	Human	Breast	IDC	5.72e-05	-1.82e-01	0.0391
114908	TMEM123	GSM4909316	Human	Breast	IDC	7.77e-06	-5.26e-01	0.21

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0070265	Breast	Precancer	necrotic cell death	11/1080	62/18723	7.54e-04	9.01e-03	11
GO:00325358	Breast	IDC	regulation of cellular component size	45/1434	383/18723	2.72e-03	2.41e-02	45
GO:00702651	Breast	IDC	necrotic cell death	11/1434	62/18723	6.92e-03	4.79e-02	11
GO:003253514	Breast	DCIS	regulation of cellular component size	44/1390	383/18723	2.58e-03	2.30e-02	44
GO:00702652	Breast	DCIS	necrotic cell death	11/1390	62/18723	5.50e-03	4.01e-02	11
GO:003253510	Endometrium	AEH	regulation of cellular component size	78/2100	383/18723	1.10e-07	5.29e-06	78
GO:00083616	Endometrium	AEH	regulation of cell size	38/2100	181/18723	9.69e-05	1.40e-03	38
GO:003253516	Endometrium	EEC	regulation of cellular component size	79/2168	383/18723	1.98e-07	8.93e-06	79
GO:000836111	Endometrium	EEC	regulation of cell size	39/2168	181/18723	8.72e-05	1.24e-03	39
GO:003253520	Esophagus	ESCC	regulation of cellular component size	227/8552	383/18723	4.77e-08	8.60e-07	227
GO:00083619	Esophagus	ESCC	regulation of cell size	107/8552	181/18723	1.81e-04	1.16e-03	107
GO:00702654	Esophagus	ESCC	necrotic cell death	39/8552	62/18723	4.68e-03	1.82e-02	39
GO:00325356	Liver	NAFLD	regulation of cellular component size	55/1882	383/18723	4.31e-03	3.55e-02	55
GO:003253512	Liver	Cirrhotic	regulation of cellular component size	135/4634	383/18723	2.32e-06	4.26e-05	135
GO:003253522	Liver	HCC	regulation of cellular component size	217/7958	383/18723	1.28e-08	3.14e-07	217
GO:00083614	Liver	HCC	regulation of cell size	95/7958	181/18723	4.15e-03	1.81e-02	95
GO:003253519	Oral cavity	OSCC	regulation of cellular component size	201/7305	383/18723	4.80e-08	8.88e-07	201
GO:00083618	Oral cavity	OSCC	regulation of cell size	92/7305	181/18723	7.86e-04	4.26e-03	92
GO:00702653	Oral cavity	OSCC	necrotic cell death	34/7305	62/18723	8.23e-03	3.00e-02	34
GO:0032535110	Oral cavity	LP	regulation of cellular component size	128/4623	383/18723	6.56e-05	8.80e-04	128

Page: 1 2

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TMEM123

insertion

Frame_Shift_Ins

novel

c.230_231insCGATACCGAA

p.Ala78AspfsTer9

p.A78Dfs*9

Q8N131

protein_coding

TCGA-AO-A0JC-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

fluorouracil

TMEM123

SNV

Missense_Mutation

c.497N>A

p.Thr166Asn

p.T166N

Q8N131

protein_coding

deleterious(0.04)

probably_damaging(0.952)

TCGA-AG-A002-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

TMEM123

SNV

Missense_Mutation

novel

c.403N>A

p.Val135Ile

p.V135I

Q8N131

protein_coding

deleterious(0.05)

benign(0.003)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

TMEM123

SNV

Missense_Mutation

novel

c.604N>T

p.Asp202Tyr

p.D202Y

Q8N131

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AP-A1E0-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

paclitaxel

TMEM123

SNV

Missense_Mutation

novel

c.254C>T

p.Thr85Met

p.T85M

Q8N131

protein_coding

deleterious(0)

probably_damaging(0.954)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

TMEM123

SNV

Missense_Mutation

novel

c.617C>T

p.Ala206Val

p.A206V

Q8N131

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AX-A0J1-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

TMEM123

SNV

Missense_Mutation

novel

c.521N>C

p.Val174Ala

p.V174A

Q8N131

protein_coding

tolerated(0.09)

benign(0.403)

TCGA-AX-A2HD-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

TMEM123

SNV

Missense_Mutation

novel

c.547N>A

p.Leu183Ile

p.L183I

Q8N131

protein_coding

deleterious(0.01)

probably_damaging(0.964)

TCGA-BS-A0UV-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

TMEM123

SNV

Missense_Mutation

novel

c.117G>T

p.Glu39Asp

p.E39D

Q8N131

protein_coding

tolerated(0.6)

benign(0.042)

TCGA-D1-A103-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

TMEM123

insertion

In_Frame_Ins

novel

c.230_231insACCGAA

p.Val77_Ala78insProAsn

p.V77_A78insPN

Q8N131

protein_coding

TCGA-A5-A0R9-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1